BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 6816636)

  • 1. Immunogenicity of cyclophosphamide-treated leukaemia cells.
    Kawalec M; Jakóbisiak M; Skórski T; Kawiak J
    Folia Biol (Praha); 1982; 28(5):334-43. PubMed ID: 6816636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide- or ifosfamide-treated L 1210 leukaemia cells: immunogenicity, viability and metabolism.
    Skórski T; Kawalec M; Hoser G
    Folia Biol (Praha); 1986; 32(5):354-65. PubMed ID: 3506526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
    Skórski T; Kawalec M
    Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
    Anderson KC; Humphrey RL; Sensenbrenner LL
    Cancer Res; 1983 May; 43(5):2030-3. PubMed ID: 6831434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
    Skórski T; Kawalec M
    Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some observations on the action of actinomycin D, mitomycin C and jawaharene on transplanted mouse fibrosarcoma.
    Roy A; Chatterjee PC
    Indian J Cancer; 1974 Dec; 11(4):394-8. PubMed ID: 4468244
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic performance of carminomycin-cyclophosphamide against L1210 leukemia.
    Avery TL; Cruze PG
    Cancer Res; 1978 Sep; 38(9):2892-5. PubMed ID: 679196
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia.
    Relyveld EH; Bizzini B; Ophir R; Ben-Efraim S
    Cancer Treat Rep; 1987 Mar; 71(3):241-6. PubMed ID: 3102055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas.
    Yu S; Lannin DR; Tsui-Collins AL; McKhann CF
    Cancer Res; 1980 Aug; 40(8 Pt 1):2756-61. PubMed ID: 7388826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing of 2,3-dihydro-1,3-6H-oxazine-dione (3-oxauracil) in mouse L1210 leukemia and 37 sarcoma.
    Stoychkov JN; Mircheva JJ
    Cancer Treat Rep; 1978 Dec; 62(12):2121-3. PubMed ID: 751720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of immune resistance against L1210 lymphatic leukemia in mice after lethal irradiation and reconstruction with fetal liver cells.
    Skórski T; Ratajczak MZ; Kawalec M; Kawiak J
    Folia Histochem Cytobiol; 1991; 29(3):121-4. PubMed ID: 1794437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum time sequence for the administration of vincristine and cyclophosphamide in vivo.
    Razek A; Vietti T; Valeriote F
    Cancer Res; 1974 Aug; 34(8):1857-61. PubMed ID: 4842737
    [No Abstract]   [Full Text] [Related]  

  • 14. The influence of schedule of administration of mitomycin C (NSC-26980) in the treatment of L1210 leukemia.
    Kojima R; Goldin A; Mantel N
    Cancer Chemother Rep 2; 1972 Nov; 3(1):111-9. PubMed ID: 4660730
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
    Kawalec M; Skórski T; Kawiak J
    Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunomodulation by antitumor antibiotics].
    Ishizuka M
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):697-700. PubMed ID: 3963840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic and nondividing mafosfamide-treated L 1210 cells--comparison of lines resistant and nonresistant to cyclophosphamide.
    Kawalec M; Hoser G; Skórski T; Kawiak J
    Folia Histochem Cytobiol; 1993; 31(2):63-6. PubMed ID: 8405569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of lymphoid leukemia colony-forming cells in Abelson virus infected mice: differences in inbred strains.
    Earl CD; Scher CD
    J Cell Physiol; 1980 Aug; 104(2):153-62. PubMed ID: 7410487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
    Stoychkov JN; Milushev AS; Todorov DK
    Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.